Basal Insulin Degludec (Tresiba) Approved for Teens and Children as Young as 1 Year Old With Diabetes

Date: 
February, 2017
January 30, 2017. The US Food and Drug Administration has approved an expanded pediatric indication for insulin degludec (Tresiba). With this indication, degludec can now be used to treat patients as young as 1 year old with type 1 or type 2 diabetes. Insulin degludec was approved for adult use in January 2016. Available research indicates that, compared with basal insulin glargine, degludec requires fewer daily injections, allows greater dosing flexibility, and is associated with a flatter blood glucose profile and less hypoglycemia.